IP Library Granted Patent US 9,908,948
Granted Patent B2
US 9,908,948 · App. 15/507,029 · Granted Mar 6, 2018

Enantiopure or enantioenriched BDDE and its use as crosslinking agent in the manufacture of cross-linked products

Inventors: Jean-Guy Boiteau (Valbonne, FR); Lars Nord (Uppsala, SE); Thibaut Gerfaud (Mouans Sartoux, FR)
Assignee: GALDERMA S.A.
C08B37/0072C07C29/10C07D301/03C07D303/24C07D303/27
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,908,948
App. No.
15/507,029
Granted
Mar 6, 2018
Kind
B2
Abstract

Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.

Claims (8)

1. A process for preparing a cross-linked hyaluronic acid product, comprising the step of cross-linking a hyaluronic acid using an enantioenriched mixture of BDDE stereoisomers, wherein one of the following enantiomers of BDDE is present in a percentage share of at least 50%:

as cross-linking agent.

2. A cross-linked hyaluronic acid product, wherein the product is produced by cross-linking a hyaluronic acid with an enantioenriched mixture of BDDE stereoisomers according to the process of claim 1 .

3. A cross-linked product according to claim 2 , wherein the cross-linked product is cross-linked via ether bonds to the BDDE.

4. A cross-linked product according to claim 2 , wherein the cross-linked product is cross-linked via ester bonds to the BDDE.

5. A cross-linked product according to claim 2 , wherein the cross-linked product is cross-linked via a mixture of ether and ester bonds to the BDDE.

6. A cross-linked product according to claim 2 , wherein the cross-linked product is a gel.

7. A cross-linked product according to claim 2 , wherein the cross-linked product is a dermal filler product.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: BOITEAU, JEAN-GUY; NORD, LARS; GERFAUD, THIBAUT
To: GALDERMA S.A.
Reel/Frame 042394/0249 →
Continuity (2)
Provisional Application 62043683 · Aug 29, 2014
Related Publication 20170291963A1 · Oct 12, 2017